See more : IVD Medical Holding Limited (1931.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Beximco Pharmaceuticals Limited (BXP.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beximco Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tokai Kisen Co., Ltd. (9173.T) Income Statement Analysis – Financial Results
- Zoglo’s Incredible Food Corp. (ZOG.CN) Income Statement Analysis – Financial Results
- Financière de Tubize SA (TUB.BR) Income Statement Analysis – Financial Results
- Ximen Mining Corp. (XXMMF) Income Statement Analysis – Financial Results
- Saddle Ranch Media, Inc. (SRMX) Income Statement Analysis – Financial Results
Beximco Pharmaceuticals Limited (BXP.L)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.beximcopharma.com
About Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.39B | 39.27B | 34.67B | 29.49B | 25.61B | 22.82B | 17.72B | 15.51B | 12.97B | 11.21B | 10.49B | 9.29B | 7.89B | 6.49B | 4.87B | 4.01B | 3.60B | 3.70B | 3.33B |
| Cost of Revenue | 24.76B | 21.95B | 18.85B | 15.57B | 13.71B | 12.20B | 9.43B | 8.32B | 6.97B | 6.10B | 5.65B | 4.90B | 4.10B | 3.32B | 2.57B | 2.00B | 1.97B | 1.97B | 1.77B |
| Gross Profit | 19.63B | 17.31B | 15.81B | 13.92B | 11.90B | 10.62B | 8.29B | 7.18B | 6.00B | 5.10B | 4.84B | 4.39B | 3.79B | 3.17B | 2.30B | 2.01B | 1.63B | 1.73B | 1.56B |
| Gross Profit Ratio | 44.23% | 44.09% | 45.61% | 47.21% | 46.46% | 46.55% | 46.77% | 46.33% | 46.28% | 45.55% | 46.12% | 47.25% | 47.99% | 48.89% | 47.29% | 50.05% | 45.30% | 46.76% | 46.84% |
| Research & Development | 0.00 | 363.02M | 281.22M | 234.68M | 180.95M | 49.46M | 49.08M | 43.23M | 36.20M | 31.05M | 27.87M | 24.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.31B | 1.17B | 1.16B | 896.65M | 792.95M | 752.94M | 618.68M | 522.40M | 448.36M | 398.76M | 375.57M | 332.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.98M |
| Selling & Marketing | 9.65B | 8.92B | 7.75B | 6.38B | 5.50B | 4.80B | 3.64B | 3.21B | 2.70B | 2.29B | 2.14B | 1.85B | 1.52B | 1.30B | 1.06B | 554.24M | 546.54M | 834.22M | 459.38M |
| SG&A | 10.96B | 10.21B | 8.91B | 7.27B | 6.29B | 5.55B | 4.26B | 3.74B | 3.15B | 2.69B | 2.51B | 2.18B | 1.52B | 1.30B | 1.06B | 554.24M | 546.54M | 834.22M | 503.36M |
| Other Expenses | 0.00 | -677.45M | 78.01M | 88.07M | 54.86M | 151.47M | 43.76M | 144.85M | 311.68M | 521.17M | 510.59M | 442.85M | 282.34M | 242.50M | 411.29M | 454.08M | 432.62M | 160.82M | 331.77M |
| Operating Expenses | 10.96B | 9.90B | 9.27B | 7.60B | 6.53B | 5.76B | 4.43B | 3.88B | 3.27B | 2.79B | 2.62B | 2.28B | 1.81B | 1.55B | 1.47B | 1.01B | 979.16M | 995.03M | 835.13M |
| Cost & Expenses | 35.72B | 32.05B | 28.13B | 23.17B | 20.24B | 17.95B | 13.86B | 12.21B | 10.23B | 8.89B | 8.27B | 7.18B | 5.91B | 4.86B | 4.03B | 3.01B | 2.95B | 2.97B | 2.60B |
| Interest Income | 0.00 | 5.53M | 3.06M | 2.38M | 20.41M | 36.46M | 54.93M | 161.11M | 304.32M | 489.97M | 512.42M | 437.20M | 330.49M | -0.09 | 32.11M | 707.45K | 15.05M | 43.79M | 2.85M |
| Interest Expense | 1.16B | 1.29B | 1.00B | 858.69M | 1.01B | 1.03B | 540.28M | 557.00M | 708.97M | 724.31M | 636.59M | 645.41M | 651.52M | 576.65M | 289.43M | 249.63M | 254.69M | 253.25M | 221.94M |
| Depreciation & Amortization | 10.81M | 2.06B | 1.67B | 203.96M | 193.82M | 166.04M | 845.91M | 98.11M | 84.95M | 90.19M | 68.91M | 68.80M | 17.01M | 15.22M | 31.44M | 16.17M | 18.85M | 6.76M | 20.17M |
| EBITDA | 8.69B | 9.37B | 8.25B | 7.39B | 5.83B | 5.13B | 4.72B | 3.53B | 3.10B | 2.90B | 2.77B | 2.59B | 2.30B | 1.94B | 1.02B | 979.92M | 673.21M | 783.27M | 727.47M |
| EBITDA Ratio | 19.56% | 23.86% | 22.18% | 24.53% | 22.13% | 21.81% | 22.02% | 22.24% | 23.49% | 25.29% | 26.02% | 27.51% | 29.71% | 29.95% | 20.99% | 24.44% | 18.59% | 20.87% | 21.87% |
| Operating Income | 8.67B | 7.22B | 6.90B | 6.65B | 5.61B | 5.07B | 4.03B | 3.45B | 2.85B | 2.42B | 2.32B | 2.21B | 1.99B | 1.64B | 1.00B | 998.82M | 654.76M | 746.51M | 724.39M |
| Operating Income Ratio | 19.54% | 18.38% | 19.91% | 22.55% | 21.90% | 22.20% | 22.73% | 22.23% | 21.99% | 21.58% | 22.16% | 23.77% | 25.20% | 25.20% | 20.57% | 24.91% | 18.20% | 20.16% | 21.77% |
| Total Other Income/Expenses | -1.15B | -1.15B | -194.80M | -273.16M | -956.05M | -1.12B | -664.83M | -556.72M | -514.15M | -308.62M | -230.68M | -298.05M | -310.63M | -274.26M | -133.79M | -284.70M | -255.10M | -223.25M | -239.03M |
| Income Before Tax | 7.53B | 6.07B | 6.69B | 6.38B | 4.65B | 3.95B | 3.36B | 2.89B | 2.34B | 2.11B | 2.09B | 1.91B | 1.68B | 1.36B | 867.51M | 714.12M | 399.67M | 523.26M | 485.36M |
| Income Before Tax Ratio | 16.95% | 15.46% | 19.29% | 21.62% | 18.17% | 17.29% | 18.97% | 18.64% | 18.03% | 18.82% | 19.96% | 20.56% | 21.26% | 20.98% | 17.82% | 17.81% | 11.11% | 14.13% | 14.59% |
| Income Tax Expense | 1.66B | 1.54B | 1.69B | 1.21B | 1.11B | 905.66M | 828.68M | 664.79M | 382.85M | 581.26M | 688.83M | 590.44M | 479.37M | 309.77M | 242.72M | 168.78M | 46.65M | 52.57M | -3.87M |
| Net Income | 5.83B | 4.61B | 5.12B | 5.13B | 3.51B | 3.03B | 2.54B | 2.23B | 1.95B | 1.53B | 1.40B | 1.32B | 1.20B | 1.05B | 624.79M | 545.34M | 353.01M | 470.69M | 489.23M |
| Net Income Ratio | 13.13% | 11.75% | 14.78% | 17.39% | 13.72% | 13.29% | 14.32% | 14.36% | 15.07% | 13.64% | 13.39% | 14.20% | 15.19% | 16.20% | 12.83% | 13.60% | 9.81% | 12.71% | 14.70% |
| EPS | 13.07 | 10.34 | 11.48 | 11.49 | 7.88 | 6.80 | 5.69 | 4.99 | 4.38 | 3.43 | 3.15 | 2.96 | 2.68 | 1.97 | 1.43 | 1.48 | 1.04 | 1.53 | 2.36 |
| EPS Diluted | 13.07 | 10.34 | 11.48 | 11.49 | 7.88 | 6.80 | 5.69 | 4.99 | 4.38 | 3.43 | 3.15 | 2.96 | 2.68 | 1.97 | 1.43 | 1.48 | 1.04 | 1.53 | 2.36 |
| Weighted Avg Shares Out | 446.11M | 446.11M | 446.11M | 446.11M | 445.92M | 446.11M | 446.11M | 446.11M | 424.87M | 446.11M | 446.11M | 446.11M | 446.11M | 535.33M | 436.51M | 369.60M | 338.80M | 308.00M | 206.78M |
| Weighted Avg Shares Out (Dil) | 446.11M | 446.11M | 446.11M | 446.11M | 445.92M | 446.11M | 446.11M | 446.11M | 446.11M | 446.11M | 446.11M | 446.11M | 446.11M | 535.33M | 436.51M | 369.60M | 338.80M | 308.00M | 206.78M |
Source: https://incomestatements.info
Category: Stock Reports